The breast cancer susceptibility gene 1 (BRCA1) is mutated in approximately 50% of hereditary breast cancers, and its expression is decreased in 30-40% of sporadic breast cancers, suggesting a general role in breast cancer development. BRCA1 physically and functionally interacts with estrogen receptor-a (ERa) and several transcriptional regulators. We investigated the relationship between cellular BRCA1 levels and tamoxifen sensitivity. Decreasing BRCA1 expression in breast cancer cells by small interfering RNA alleviated tamoxifen-mediated growth inhibition and abolished tamoxifen suppression of several endogenous ER-targeted genes. ER-stimulated transcription and cytoplasmic signaling was increased without detectable changes in ER or ER coregulator expression. Co-immunoprecipitation studies showed that with BRCA1 knockdown, tamoxifen-bound ERa was inappropriately associated with coactivators, and not effectively with corepressors. Chromatin immunoprecipitation studies demonstrated that with tamoxifen, BRCA1 knockdown did not change ERa promoter occupancy, but resulted in increased coactivator and decreased corepressor recruitment onto the endogenous cyclin D1 promoter. Our results suggest that decreased BRCA1 levels modify ERa-mediated transcription and regulation of cell proliferation in part by altering ERacoregulator association. In the presence of tamoxifen, decreased BRCA1 expression results in increased coactivator and decreased corepressor recruitment on ERregulated gene promoters.
Introduction
The steroid hormone 17b-estradiol (E2), acting through estrogen receptors (ERa and ERb), plays an important role in development and progression of breast cancer (Doisneau-Sixou et al., 2003) . Breast cancer occurrence is linked to E2 exposure, and approximately 75% of breast tumors express ERs (Dowsett et al., 2006) . E2 induces cell proliferation at least partially by stimulating progression through the G1 phase of the cell cycle (Doisneau-Sixou et al., 2003) . Acting through ERs, E2 regulates transcription of responsive genes, some of which control cell proliferation and apoptosis (Basu and Rowan, 2005) . Both ER subtypes are members of the nuclear receptor superfamily and present in normal mammary cells, but ERa is expressed at higher levels in tumors (Doisneau-Sixou et al., 2003) . ER-mediated transcription can be inhibited by anti-estrogens, which suppress ER activity and cell proliferation. Tamoxifen (Tam), an anti-estrogen, reduces breast cancer recurrence and mortality in women with ER-positive tumors (Fink, 2006) . However, 30-50% of women with ERpositive tumors do not initially respond to Tam, exhibiting intrinsic resistance, and patients with initially positive responses may suffer a recurrence, displaying acquired resistance (Clarke et al., 2003) . Thus, it is important to identify molecular mechanisms of Tam resistance to better predict therapeutic responses.
In the presence of ligand ER undergoes conformational changes, dimerizes and binds to DNA sequences such as estrogen response elements (EREs), or forms complexes with other transcription factors bound to target gene promoters (Hall et al., 2001) . E2-bound ER recruits coactivators, which serve as a bridge between ER and general transcription machinery, or are associated with histone acetyltransferases to stimulate transcription (Shang et al., 2000) . Tam-bound ER does not bind coactivators, but instead binds corepressors, which inhibit gene transcription by recruiting histone deacetylases (Kurtev et al., 2004) . Therefore, ER coregulators play a critical role in regulating ER transcription. Changes in coregulator activity or expression may alter ER activity and response to different ligands (Smith and O'Malley, 2004) .
The protein product of the breast cancer susceptibility gene1 (BRCA1) directly interacts with ERa, primarily through its N-terminus , and inhibits ERa transcription (Fan et al., 1999) . BRCA1 germ-line mutations have been identified in approximately 50% of hereditary breast cancers and 80% of cases with both hereditary breast and ovarian cancers (Narod and Foulkes, 2004) . However, most breast cancers are sporadic, with only 5-10% due to inherited susceptibility (Bissonauth et al., 2008) . Decreased BRCA1 expression due to promoter hypermethylation or loss of one BRCA1 allele (Magdinier et al., 1998) was shown in 30-40% of sporadic breast cancers (Birgisdottir et al., 2006) . Thus, BRCA1 may generally play a role in breast cancer development.
BRCA1 is a predominantly nuclear phosphoprotein with 1863 amino acids (Chen et al., 1996) . It has several functional domains, including an N-terminal RING finger, central region nuclear localization signals and two BRCA1 C-terminal domains. The RING finger domain is important for association with several proteins, particularly BARD1 (Wu et al., 1996) . BRCA1-BARD1 complexes display ubiquitin E3 ligase activity and are involved in protein ubiquitination (Hashizume et al., 2001) . The BRCA1 C-terminal domains are involved in DNA damage repair (Glover et al., 2004) and association with components of basal transcription machinery such as RNA polymerase II (Krum et al., 2003) , ER coregulators such as p300/CBP (cyclic AMP response element binding protein binding protein) (Fan et al., 2002) and chromatin modification proteins such as histone deacetylases 1/2 (Yarden and Brody, 1999) .
In this study, we investigated potential links between decreased BRCA1 levels and responses to Tam in ERpositive human breast cancer cell lines (T47D and ZR-75-1). We showed that BRCA1 knockdown abolished Tam suppression of cell proliferation and ERa transcriptional activity. This occurred not through altered protein expression of ERs or ER coregulators, but by promoting ER-coactivator interactions and decreasing ER-corepressor association in the presence of Tam. On the basis these findings, we suggest decreased BRCA1 levels alter ER-coregulator interactions to make ERamediated transcription less responsive to Tam, thus contributing to Tam-resistant phenotypes.
Results

BRCA1 knockdown alters proliferation responses of breast cancer cells to Tam
To investigate effects of decreased BRCA1 expression, BRCA1 small interfering RNA (siRNA) oligonucleotides (DO3 or DO7) were used to knockdown endogenous BRCA1 in T47D (Hu et al., 2005) and ZR-75-1 ER-positive breast cancer cells. Figure 1a shows BRCA1 protein expression was efficiently decreased in both DO3-and DO7-transfected T47D cells. BRCA1 in parental T47D cells is present predominantly as the full-length (220 kDa) protein, with only a minor fraction as shorter isoforms. All isoforms were efficiently eliminated by siBRCA1 (data not shown). To determine whether decreased BRCA1 expression altered DNA synthesis, a measure of cell proliferation, BrdU incorporation was analyzed. In cells transfected with control siRNA (siCon), BrdU incorporation was significantly stimulated by 17b-estradiol (E2, 10 nM) and suppressed by 4-hydroxytamoxifen (Tam, 1 mM or 10mM). In BRCA1 knockdown cells with either siRNA (DO3 or DO7), E2 remained stimulatory, but Tam was no longer suppressive (compare checkered and hatched bars with siCon). However, lentivirus re-expression of silent mutant BRCA1 protein (silent mut.) rescued Tam suppression of DNA synthesis (Figure 1b ). BRCA1 protein was efficiently decreased in DO7-transfected ZR-75-1 cells compared with siCon-transfected cells, and Tam-induced growth inhibition was abolished in BRCA1 knockdown cells ( Figure 1c ). These data indicated that BRCA1 protein levels can regulate cell sensitivity to Tam.
These results could not be explained by altered levels of ERa, ERb, ER coactivators (SRC1 and SRC3) or corepressors (silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) and repressor of estrogen receptor activity (REA)) ( Figure 2a ). BRCA1 knockdown also did not change normalized ERa or ERb protein levels in the presence of ligand (Figures 2b and c) . Consistent with published results (Horner-Glister et al., 2005) , E2 treatment decreased ERa to 20% and ERb to 70% of untreated levels within 24 h in both siCon-and siBRCA1-transfected cells (Figure 2b ). Tam treatment did not appreciably decrease ER protein levels even after 24 h in cells with endogenous or decreased BRCA1 (Figure 2c ).
BRCA1 knockdown alleviates Tam suppression of ER-regulated gene transcription
To assess mechanisms by which BRCA1 knockdown rendered cell proliferation less responsive to Tam suppression, we first investigated ER transcriptional activity with a transfected luciferase reporter (pGL3-2ERE) containing two tandem EREs. E2-stimulated ERE-dependent transcription was significantly enhanced in BRCA1 knockdown cells ( Figure 3a ). Tam treatment slightly increased transcription in BRCA1 knockdown cells, and responses to E2 þ Tam were significantly enhanced compared with control cells, indicating that Tam suppression of ERE activity was also decreased. Cotransfection of ERa siRNA dramatically decreased ERE activity. In BRCA1 and ERa double-knockdown cells, no stimulation was observed with Tam or E2 þ Tam, indicating that BRCA1 knockdown-induced loss of Tam suppression required ERa protein.
We next tested ER activity on endogenous genes, including progesterone receptor (PR), c-Myc and cyclin D1, which are E2-stimulated and involved in either proliferation or cell-cycle progression (Dubik and Shiu, 1992; Graham et al., 1995; Kenny et al., 1999) . In control cells, mRNAs for PR (Figure 3b ), c-Myc ( Figure 3c ) and cyclin D1 ( Figure 3d ) were decreased 40-50% by Tam, and were either significantly (c-Myc) or moderately increased (PR and cyclin D1) by E2 at these time points. However, in cells transfected with siBRCA1, Tam suppression of all three genes was eliminated and E2 stimulation was enhanced at the same time point. Stimulation by E2 þ Tam for these genes was also significantly enhanced in BRCA1 knockdown cells, indicating that Tam suppression of E2-stimulated transcription was decreased. There was no Tam stimulation of any endogenous gene. Similar results were observed for cyclin D1 mRNA in ZR-75-1 cells (Figure 3e ). Together, these results show that decreased expression of BRCA1 modulates ER-mediated tran-scription and abrogated Tam suppression of endogenous ER target genes.
Decreased BRCA1 expression alters ERa-coregualtor association
As knockdown of endogenous BRCA1 does not affect protein levels of ER coregulators (Figure 2a ), or ERa and ERb in the presence of ligand (Figures 2b and c) , other mechanisms must regulate ER transcriptional activity. BRCA1 can associate not only with ERa, but also with many ER coregulators and general transcription factors, and thus may alter interactions between (a) T47D cells (4 Â 10 6 cells) were nucleofected with 2 mg of control siRNA (siCon) or BRCA1 siRNA (siBRCA1, DO3 or DO7 oligonucleotides) together with 2 mg of GFP expression vector. After 36 h, cells were serum starved overnight then treated with ethanol vehicle (V), 10 nM E2, 1 mM or 10 mM Tam for 24 h. BrdU was added during the last 4 h of treatment. BRCA1 protein levels are shown in western blots insets. (b) T47D cells (4 Â 10 6 cells) were transfected as in (a). After 24 h, DO7-transfected cells were infected with Lentivirus containing either empty vector (Vec) or the BRCA1 DO7 silent mutation (silent mut). After 16 h of infection, cells were serum starved overnight then treated with vehicle, 10 nM E2 or 1 mM Tam for 24 h and scored for BrdU incorporation. (c) ZR-75-1 cells (4 Â 10 6 cells) were transfected as in (a). Cells were then infected with Lentivirus and BrdU incorporation was measured as described in (b). All BrdU results are the mean of three experiments; a representative blot is shown. Two-way ANOVA was used to determine statistical significance. *Po0.05 treatment vs vehicle;^Po0.05 siBRCA1 vs siCon group for the same treatment. ANOVA, analysis of variance; GFP, green fluorescent protein.
ERa and regulatory proteins. To evaluate effects of decreased BRCA1 expression on ERa-coregulator interactions, immunoprecipitation assays were per-formed. Figure 4a shows that in control T47D cells, E2 but not Tam treatment increased association between ERa and the coactivator SRC3 approximately Figure 2 BRCA1 knockdown did not alter ER coregulator protein levels or ER levels in the presence of ligand. (a) T47D cells (4 Â 10 6 cells) were nucleofected with 2 mg of either siCon or siBRCA1 (DO7). After 48 h, cells were collected and lysed in SDS lysis buffer plus protease inhibitors. Total protein lysate (50 mg) was separated by 5-10% gradient SDS-PAGE, transferred to nitrocellulose membrane and immunoblotted with indicated antibodies. (b and c) T47D cells were nucleofected with siCon or siBRCA1 (DO7). After 48 h, cells were treated with 10 nM E2 (b) for 0, 0.5, 1 and 24 h, or treated with 1 mM Tam (c) for 0, 1, 12 and 24 h and then lysed in SDS lysis buffer plus protease inhibitors. Protein lysate (20 mg) was separated by 8% SDS-PAGE and probed for ERa, ERb and b-actin.
Intensities of ERa, ERb and b-actin bands on individual films were measured by densitometry and analyzed with ImageQuant (Molecular Dynamics, Inc., Sunnyvale, CA, USA). ERa and ERb protein levels were normalized to b-actin in each sample, and ERa and ERb protein levels in each sample were expressed relative to the vehicle-treated siCon-transfected cells, which were set at 1.0. Each experiment was repeated at least three times. Representative blots from one of three independent experiments are shown. Two-way ANOVA was used to determine statistical significance. *Po0.05 treatment vs vehicle control. ANOVA, analysis of variance. and SMRT (Fleming et al., 2004) were also tested. Figure 4b shows that in control cells, ERa-REA association decreased by 45% with E2, and increased 2.4-fold with Tam compared with vehicle. However, in BRCA1 knockdown cells, association between ERa and REA was dramatically decreased in both vehicle-and Tam-treated cells compared with control cells. Similarly, Tam-induced ERa-SMRT association was also decreased in BRCA1 knockdown cells. Taken together, these data suggest that in the absence of BRCA1, Tambound ERa aberrantly recruits coactivators, but does not recruit corepressors as efficiently as in control cells.
BRCA1 knockdown alters association of ER coregulators with the cyclin D1 promoter
We next determined if BRCA1 knockdown affects recruitment of ERa and/or its coregulators onto BRCA1 knockdown induced tamoxifen resistance J Wen et al the promoter of an endogenous E2-responsive gene. We chose cyclin D1 promoter because it plays a critical role in cell-cycle progression. Control and BRCA1 knockdown T47D cells were exposed to either 10 nM E2 or 1 mM Tam for 0-60 min. In Figure 5 , open squares represent protein association with the promoter in control cells and solid triangles represent associations in BRCA1 knockdown cells. In the presence of E2 (Figure 5a ), ERa promoter binding exhibited a cyclical pattern in both control and BRCA1 knockdown cells, as observed for other E2-responsive genes (Reid et al., 2003) . Overall, E2-ERa recruitment was not significantly changed by decreased BRCA1 expression. Similarly, in the presence of Tam, ERa promoter occupancy was comparable in control and BRCA1 knockdown cells. BRCA1 was significantly associated with the promoter in Tam-treated siCon cells (Figure 5b ), but not in BRCA1 knockdown cells. With Tam treatment, the corepressor SMRT was significantly associated with the promoter in siCon-transfected cells, but not in siBRCA-transfected cells. In contrast, in Tam-treated siCon-transfected cells no significant association of SRC3 or CBP with the promoter was observed (Figure 5c ), whereas, in cells with decreased BRCA1, association of both SRC3 and CBP was dramatically increased. Taken together, chromatin immunoprecipitation results showed that with Tam treatment decreased BRCA1 expression did not significantly alter ERa recruitment on a target gene promoter, but increased recruitment of ER coactivators and decreased recruitment of ER corepressors. This would contribute to lack of suppression of ER-regulated gene transcription, and ultimately cell proliferation, in the presence of Tam.
BRCA1 knockdown upregulates E2-induced mitogenactivated protein kinase (ERK1/2) and Akt activity Previous studies showed that BRCA1 overexpression inhibited membrane ER and epidermal growth factor receptor signaling in breast cancer cells (Razandi et al., 2004) . To explore effects of decreased BRCA1 expression on ER cytoplasmic signaling, we examined control and BRCA1 knockdown cells for mitogen-activated protein kinase (MAPK) (ERK1/2) and Akt (protein kinase B) activation in response to E2 or Tam. In (Figure 6a ). BRCA1 knockdown significantly enhanced only E2-stimulated MAPK activation in terms of both kinetics and magnitude. E2, but not Tam-induced Akt phosphorylation (S473), was also enhanced in BRCA1 knockdown cells, with E2 activation occurring earlier and to a greater extent (Figure 6b ). These data suggest that endogenous BRCA1 has inhibitory effects on E2stimulated MAPK and Akt activation. Elevated MAPK or Akt activity could stimulate ERa activity by increasing phosphorylation of serine residues in ERa AF-1 domain, including the well-characterized MAPKsensitive ERa serine118 (S118) site (Murphy et al., 2004) . Figure 6c shows that ERa S118 phosphorylation was stimulated by E2 but not Tam in both control and BRCA1 knockdown cells, but there was no significant difference with BRCA1 knockdown. The growth factor receptor, HER2, was also examined. No E2-or Taminduced HER2 phosphorylation was detected in our siCon-or siBRCA1-tranfected cells (Figure 6d ). However, EGF stimulated HER2 phosphorylation in control cells, which was further enhanced in BRCA1 knockdown cells. This is consistent with previous work showing BRCA1 overexpression inhibited EGF-stimulated signaling (Razandi et al., 2004) .
Discussion
The development of intrinsic or acquired resistance to ER-directed agents in breast cancer therapy is of great therapeutic interest (Clarke et al., 2001) . In this report we found that decreased BRCA1 expression in T47D and ZR-75-1 breast cancer cells results in decreased responsiveness to the anti-estrogen Tam. Previous work showed that Tam promoted mammary epithelial cell proliferation and cancer development in a mouse model of mammary gland Brca1-deficiency (Jones et al., 2005) , and defective BRCA1 levels in ovarian cancer cells resulted in differential altered responses to several chemotherapeutic anti-estrogen drugs (Srinivas et al., 2004; Thasni et al., 2008) . These data, and studies demonstrating direct suppressive effects of BRCA1 on ER function (Fan et al., 2001) , suggest that cellular levels of BRCA1 play a role in breast cancer development, cell proliferation in response to ER ligands, and sensitivity to Tam. Figure 6 BRCA1 knockdown upregulates E2-induced MAPK (ERK1/2) and Akt activation. T47D cells (4 Â 10 6 cells) were nucleofected with 2 mg of either siCon or siBRCA1 (DO7) and incubated for 48 h, followed by treatment with ethanol vehicle (V), 10 nM E2 or 1 mM Tam for 5, 10 or 15 min as shown. Protein lysate (20 mg) was separated by 10% SDS-PAGE and immunoblotted for total and phosphorylated MAPK (ERK1/2) (a), total and phosphorylated Akt (S473) (b), total and phosphorylated ERa (S118) (c) and b-actin as a loading control (not shown). (d) After 48 h of nucleofection, both control and BRCA1 knockdown cells were treated with ethanol vehicle (V), 10 nM E2 or 1 mM Tam for 15 min, or 100 ng/ml hEGF for 3 min. Protein lysate (80 mg) was separated by 5% SDS-PAGE and immunoblotted for total and phosphorylated HER2 (Y1248). Blots shown are representative examples of three individual experiments. Bars represent densitometric analysis of bands expressed as phosphorylated protein levels normalized for total immunopositive protein (kinase, ERa or HER2 protein levels) from three experiments, and expressed relative to siCon, vehicle-treated cells (1.0). Two-way ANOVA was used to determine statistical significance. *Po0.05 treatment vs vehicle,^Po0.05 siBRCA1 vs siCon group for the same treatment. ANOVA, analysis of variance.
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Our data demonstrate that decreasing BRCA1 expression with two separate siRNAs in T47D or ZR-75-1 cells abolished Tam-induced growth inhibition (Figure 1 ). Inhibition could be restored after reexpression of BRCA1 protein resistant to siRNA. BRCA1 has a RING finger domain, and may serve as an ubiquitin ligase (Hashizume et al., 2001) . Although in vitro studies suggested ERa monoubiqutination, which is not associated with protein degradation, may occur in the presence of BRCA1 (Eakin et al., 2007) , we observed no effect of BRCA1 knockdown on protein levels of ERa, ERb, or ER coregulators (Figure 2a ), or in steady state ER levels with E2 or Tam (Figures 2b and c) . These data suggest BRCA1 does not directly regulate ER turnover in breast cancer cells.
In the absence of BRCA1, we observed increased ERa transcriptional activity with a luciferase reporter gene (Figure 3a) . This is consistent with previous work showing that ERa transcription on reporter genes was decreased by BRCA1 overexpression (Fan et al., 1999; Zheng et al., 2001) . Similarly, BRCA1 globally inhibits the E2 effects on gene expression in breast cancer cells (Xu et al., 2005) . Knockdown of endogenous ERa significantly decreased ERE activity and inhibited the stimulatory effect of Tam in the BRCA1 and ERa double-knockdown cells, showing that these BRCA1 knockdown-induced Tam effects are ERa dependent. We examined the effect of BRCA1 knockdown on the transcription of endogenous E2-responsive genes, including PR, c-Myc and cyclin D1 (Figures 3b-e ). These genes are important for mammary gland differentiation and ductal branching throughout the menstrual cycle and pregnancy (PR), or for cell proliferation (c-myc and cyclin D1), and are stimulated by E2-ER through a variety of tethered transcription factors (Dubik and Shiu, 1992; Sabbah et al., 1999; Petz et al., 2004) . Overexpression of c-Myc occurs in 20-30% of human breast cancers (Dubik and Shiu, 1992) , and cyclin D1 is required for Tam-induced cell-cycle progression in human breast cancer cells (Kilker and Planas-Silva, 2006) . In T47D BRCA1 knockdown cells, E2 stimulation of all three genes is enhanced compared with control cells, Tam suppression was eliminated and Tam suppression of E2-stimulated gene transcription was decreased. Similar results were observed for cyclin D1 in ZR-75-1 cells (Figure 3e ), indicating that this is not a cell-specific phenomenon. These data suggest the Tamresistant phenotype induced by decreased BRCA1 expression may result as least partially from the loss of Tam suppression of ERa transcriptional activity. In contrast to the ERE reporter, no Tam stimulation was observed with endogenous genes. Because ERE-luciferase is only a synthetic reporter, it may not faithfully recapitulate all aspects of ER function on cell proliferation. Thus, Tamoxifen-alone stimulation of the reporter can differ from the results with BrdU incorporation, or on endogenous mRNAs that are regulated through complex response elements rather than simple EREs (Figures 1 and 3) .
Appropriate ERa responses to Tam depend on appropriate function and expression of ER coregulators (de Mora and Brown, 2000; Kurtev et al., 2004) . E2-bound ERa stimulates transcription through coactivator recruitment (de Mora and Brown, 2000) , whereas Tam-bound ERa inhibits transcription by recruiting corepressors and preventing coactivator binding (Liu and Bagchi, 2004) . Elevated expression or enhanced activity of coactivators and/or decreased expression of corepressors have all been reported to alter Tam responses in tissue culture or human tumors (Murphy et al., 2000; Shang and Brown, 2002; Girault et al., 2003) . In our studies, altered ER coregulator expression cannot account for Tam resistance induced by decreased BRCA1, as there were no detectable changes in levels of any tested coactivators or corepressors (Figure 2a ). Instead, our co-immunoprecipitation assays showed that BRCA1 knockdown increased ERa-coactivator (SRC3 and SRC1) association and decreased ERacorepressor (REA and SMRT) association in the presence of Tam (Figure 4 ). We next examined whether recruitment of ERa and its coregulators to the cyclin D1 gene promoter varied with BRCA1 levels. BRCA1 associates with ERa at the promoter of endogenous E2-responsive genes (Zheng et al., 2001) , and we observed that Tam treatment resulted in BRCA1 association with the cyclin D1 promoter in control cells, but not in BRCA1 knockdown cells (Figure 5b) . Chromatin immunoprecipitation assays showed that in the absence of BRCA1, Tam treatment significantly increased association of ER coactivators (SRC3 and CBP) but decreased association of the corepressor (SMRT) with the promoter (Figures 5b and c) . Decreased BRCA1 expression did not significantly alter recruitment of ERa to the cyclin D1 promoter with either E2 or Tam (Figure 5a ), suggesting that it is the altered association of ERa with coregulators that contributes to the inappropriate Tam response.
BRCA1 is predominantly a nuclear protein, but may also play a role in cytoplasmic signaling transduction. Overexpression of wild-type, but not mutant, BRCA1 in MCF-7 and ZR-75-1 cells inhibited MAPK activation and cell proliferation in response to E2, EGF and IGF-1 (Razandi et al., 2004) , and cross talk between ER and growth factor pathways plays an important role in breast cancer cell proliferation (Shupnik, 2004) . In addition, upregulation of growth factor signaling modulated BRCA1 suppression of ERa activity, in part through serine phosphorylation of the ERa AF-1 domain . In this study, BRCA1 knockdown resulted in higher and more rapid E2-stimulated MAPK (ERK1/2) and Akt activation (Figures 6a and b ). This is consistent with an earlier report that BRCA1 knockdown in MCF-7 cells increased E2-ER stimulation of MAPK (Razandi et al., 2004) . ERa-S118 is a MAPK substrate (Murphy et al., 2004) and its phosphorylation was detected after E2 treatment (Figure 6c ), but with no significant difference between control and BRCA1 knockdown cells. However, additional targets of MAPK or Akt, such as coregulators, may have increased phosphorylation in BRCA1 knockdown cells and contribute to altered activity or protein-protein associations between ER and coregulators and/or the transcriptional machinery. HER2 phosphorylation was not stimulated by either E2 or Tam in control or BRCA1 knockdown cells (Figure 6d ), indicating that it was not significantly regulated by ER cytoplasmic signaling in these cells, although other epidermal growth factor receptor family members may play a role in this pathway. Tam alone had no effects seen only in BRCA1 knockdown cells.
As BRCA1 associates with ERa (Fan et al., 2001) and proteins that alter ER function, such as CBP/p300 (Fan et al., 2002) , RNA polymerase II (Krum et al., 2003; Starita et al., 2005) and histone modification enzymes (Yarden and Brody, 1999) , BRCA1 may play a functional role in associations between these molecules. With BRCA1 knockdown, functional proximity between ERa and its coregulators or the physical sites of protein interaction may be altered, leading to inappropriate recruitment of coregulators by ERa onto target gene promoters. In the presence of Tam, these inappropriate protein-protein associations on the promoter would lead to altered transcriptional activity of ERa and gene transcription that ultimately leads to upregulated cell proliferation or failure to be suppressed by Tam. Thus, intrinsic resistance to Tam in some ERpositive breast cancers may be because of reduced BRCA1 in these tumors. It will be interesting for future studies to test similar pathways for additional SERMS (selective estrogen receptor modulators) or therapies that target ER. On the basis of these findings, BRCA1 may serve as a potential additional biomarker for prediction of hormonal sensitivity of ER-positive breast cancer.
Materials and methods
Cell culture T47D human breast carcinoma cells were grown in Dulbecco's modified eagle's medium (Mediatech, Herndon, VA, USA) supplemented with 10% fetal bovine serum and 1% Antibiotic-Antimycotic (Life Technologies, Grand Island, NY, USA). ZR-75-1 human breast carcinoma cells were cultured in RPMI-1640 (Invitrogen, Grand Island, NY, USA) with 10% fetal bovine serum, 1% penicillin/streptomycin (Invitrogen). For all experiments, cells were plated and treated in phenol red-free medium supplemented with charcoal-stripped serum. Cells were maintained at 37 1C in 5% CO 2 /95% air.
Antibodies and reagents
Anti-ERa antibody (HC-20) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA) or (1D5) Dako (Carpinteria, CA, USA), anti-ERb was from Upstate (Lake Placid, NY, USA). Anti-BRCA1 (Ab-1) was from CalBiochem (San Diego, CA, USA). Anti-SRC3 and anti-CBP were from Santa Cruz Biotechnology. Anti-SRC1 was from Affinity BioReagents (Golden, CO, USA), anti-SMRT from BD Biosciences (San Jose, CA, USA) and anti-REA from Novus Biologicals (Littleton, CO, USA). Antibodies for phospho-ERa (S118), total and phospho-MAPK (p44/42), total and phospho-Akt (S473) were from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibodies for total and phospho-HER2 (Y1248) were from Santa Cruz and Invitrogen. 5-Bromo-2 0 -deoxyur-idine was from Sigma-Aldrich Corp (Saint Louis, MO, USA) and anti-BrdU antibody was from Molecular Probes (Eugene, OR, USA). 17b-estradiol and 4-hydroxytamoxifen were from Sigma-Aldrich Corp.
siRNA transfection and immunoblotting
To knockdown BRCA1 expression, siGENOME siRNA reagents, D-003461-03 (DO3) and D-003461-07 (DO7) (Dharmacon Inc. Chicago, IL, USA), targeting human BRCA1 mRNA were used as described (Hu et al., 2005) . ERa siRNA, siERa (003401) and nontargeting siRNA, siCon (D-001210-01-20) were from Dharmacon Inc. T47D and ZR-75-1 cells (4 Â 10 6 ) were transfected with 2 mg of either siCon or siBRCA1 by nucleofection and plated into 35 mm wells (Fox et al., 2008) . After 48 h of transfection, cells were collected in lysis buffer (31.25 mM Tris, pH ¼ 6.8, 12.5% glycerol, 1% SDS) plus protease inhibitors. Protein concentration was determined using the bicinchoninic acid protein assay (Pierce Chemical Co., Rockford, IL, USA). Protein lysates (50 mg) were separated by gradient (5-10%) SDS-PAGE and transferred to nitrocellulose membranes. Specific proteins were detected as described (Fox et al., 2008) .
Bromodeoxyuridine incorporation T47D and ZR-75-1 cells (4 Â 10 6 ) were nucleofected with 2 mg of either siCon or siBRCA1 and 2 mg of green fluorescent protein as a transfection marker. Cells were grown on Poly-Llysine (Sigma-Aldrich)-coated cover slips and allowed to proliferate for 36 h followed by serum starvation overnight. Cells were then treated with ethanol vehicle, 10 nM E2, 1 or 10 mM Tam for 24 h. Bromo-deoxyuridine (BrdU) was added during the last 4 h, cells were fixed, stained and scored for BrdU incorporation as described (Fox et al., 2008) . Experiments were repeated three times.
Lentiviral gene expression
Lentiviral stocks were produced in 293T cells (provided by Dr Anindya Dutta) by transfecting constructs (vector and BRCA1-DO7 silent mutant), packaging plasmid (pMD2.G) and envelope plasmid (psPAX2) using Lipofectamine-2000 (Invitrogen) . Virus was harvested 48 h post transfection, filtered through a 0.45 mm filter and stored at 4 1C. Before infection, 4 Â 10 6 T47D or ZR-75-1 cells were nucleofected with siRNA and green fluorescent protein, and plated onto coated cover slips for measuring BrdU incorporation or into 35 mm wells for protein expression. Titering experiments were performed to determine virus amounts needed to rescue BRCA1 expression. After 24 h of nucleofection, virus was applied to cells grown in phenol red-free Dulbecco's modified eagle's medium containing stripped serum and polybrene (8 mg/ml) (Millipore, Phillipsburg, NJ, USA). Cells were incubated at 37 1C for 16 h before serum starvation overnight and subsequent treatment and BrdU incorporation.
Luciferase assay T47D cells (4 Â 10 6 ) were nucleofected with 2 mg of total siRNA and 1 mg of pGL3-2ERE luciferase reporter plasmid (Schreihofer et al., 2001) , then plated into 22 mm wells. After 24 h, cells were treated with ethanol vehicle, 10 nM E2, 1 mM Tam or E2 þ Tam for 24 h, then collected and assayed for luciferase activity (Tsai et al., 2004) . Each treatment was in triplicate, for three experiments.
Real-time RT-PCR T47D and ZR-75-1 cells (4 Â 10 6 ) were nucleofected with 2 mg of siCon or siBRCA1, then plated into 60 mm wells and incubated for 24 h followed by serum starvation overnight. Time course experiments were performed with ethanol vehicle, 10 nM E2, 1 mM Tam or E2 þ Tam for 1, 4 and 24 h. Time points were chosen for each gene based on the maximum Tam suppressive effects. RNA was extracted and reverse transcribed into cDNA, which was used for real-time RT-PCR (Fox et al., 2008) . b-actin was measured as a control and was unaffected by BRCA1 knockdown or treatments. PCR conditions and cycle numbers were adjusted thus each reaction fell within the linear range of product amplification. Primers for cyclin D1, c-Myc and b-actin were described (Fox et al., 2008) . PR primers are forward: 5 0 -ACAGGACCCCTCC GACGAAAA-3 0 and reverse: 5 0 -GGTGCAAGGTTGGAGA CAGCT-3 0 .
Immunoprecipitation and phosphorylation studies Cells (4 Â 10 6 ) were nucleofected with 2 mg of siCon or siBRCA1 then plated into 10 cm dishes. After 48 h, cells were treated with ethanol vehicle, 10 nM E2 or 1 mM Tam for 45 min, resulting in maximal association of ER and coregulators with least amount of ER degradation in the presence of E2. Cells were collected in 250 ml Mammalian Protein Extraction Reagent (Pierce Chemical Co.) plus protease inhibitors. Protein concentration was measured using the bicinchoninic acid protein assay. Immunoprecipitation was performed by overnight incubation of anti-ERa (HC20) with lysates containing equivalent amounts of ERa protein determined by western blot, then adding protein G-agarose (Santa Cruz) and incubation at 4 1C for 1 h. Agarose pellets were washed three times with RIPA buffer and bound proteins were eluted by boiling for 5 min in buffer (250 mM Tris-HCl pH ¼ 6.8, 4% SDS, 10% b-ME, 20% glycerol). Eluted proteins were separated on a 5-10% gradient SDS-PAGE and transferred onto nitrocellulose membranes for immunoblotting.
For phosphorylation studies, cells were collected and lysed in gel-loading buffer plus protease inhibitors and sodium orthovanadate, then immediately boiled at 95 1C for 5 min.
Protein lysate (20 mg) was separated by 10% SDS-PAGE (for MAPK, Akt and ERa) or (for HER2, 80 mg) by 5% SDS-PAGE, then immunoblotted for total and phosphorylated proteins.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed as described (Curtin et al., 2004) . Cross-linked chromatin lysates were sonicated and diluted with ChIP sonication buffer plus protease inhibitors (0.2 mg/ml leupeptin and aprotinin, 20 mM phenylmethanesulphonylfluoride), divided and incubated with normal rabbit serum, antibodies to ERa (HC20), BRCA1, SMRT, SRC3 or CBP at 4 1C overnight, then precipitated with protein G-agarose. Cross-linking was reversed by overnight 65 1C incubation. DNA fragments were extracted with PCR purification kit (Qiagen, Valencia, CA, USA) and quantitated by real-time PCR as described (Ferris et al., 2007) . Cyclin D1 promoter primers were forward: 5 0 -TCTTGGGCTGCT GCTGCTGGAAT-3 0 and reverse: 5 0 -GTCGTTGCAAATG CCCAAGG-3 0 . Experiments were performed in duplicate, three times.
Statistical analyses
Statistical significance was determined by two-way analysis of variance using GraphPad Prism 4.00 for Windows (GraphPad Software, San Diego, CA, USA) and Bonferroni post hoc analysis with Po0.05 considered significant.
